UK markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.1500-0.0700 (-2.17%)
At close: 04:00PM EDT
3.2400 +0.09 (+2.86%)
After hours: 06:06PM EDT

Omeros Corporation

The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119
United States
206 676 5000
https://www.omeros.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees213

Key executives

NameTitlePayExercisedYear born
Dr. Gregory A. Demopulos M.D.Co-Founder, Chairman, CEO & Pres1.74M2.68M1959
Mr. Michael A. JacobsenChief Accounting Officer, VP of Fin. & Treasurer505.32k348.51k1958
Mr. Peter B. Cancelmo J.D.VP, Gen. Counsel & Corp. Sec.478.19kN/A1979
Dr. Pamela Pierce Palmer M.D., Ph.D.Co-FounderN/AN/A1963
Dr. George A. Gaitanaris M.D., Ph.D.Chief Scientific Officer & VP of ScienceN/AN/A1957
Mr. Peter W. WilliamsVP of HRN/AN/A1968
Dr. J. Steven Whitaker J.D., M.D.VP of Clinical Devel. & Chief Medical OfficerN/AN/A1956
Dr. Catherine A. Melfi Ph.D.Chief Regulatory Officer & VP of Regulatory Affairs and Quality SystemsN/AN/A1959
Ms. Nadia DacVP & Chief Commercial OfficerN/AN/A1970
Ms. Debra K. Bowes M.TChief Bus. Devel. OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Corporate governance

Omeros Corporation’s ISS governance QualityScore as of 28 September 2022 is 8. The pillar scores are Audit: 6; Board: 10; Shareholder rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.